Rechercher des projets européens

29 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Targeted small-molecule Stabilisation of Protein-Protein Interactions (TASPPI)

Date du début: 1 févr. 2016, Date de fin: 31 janv. 2020,

...aries between academia and industry and to increase their employability in both areas. To this end we have teamed up in a consortium comprising 5 partners from industry (AstraZeneca, GlaxoSmithKline, UCB, Lead Disocvery Center, Taros Chemicals) and 6 partners from academia (Universities of Dundee, Eindhoven, Leeds, Lille, Prague, and Siena). The scientific objective of the multi-sectorial Training ...
Voir le projet

 10

 TERMINÉ 

ISOTOPIC LABELING FOR DRUG INNOVATION (ISOTOPICS)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

Excessive attrition rates during clinical trials dramatically impact on Drug Discovery and Development (DDD). Absorption, Distribution, Metabolism and Excretion studies carried out on larger series of drug candidates at an earlier stage of the DDD timeline and evaluation of drug efficacy through better assessment of pharmacokinetic/pharmacodynamic relationships, target engagement and receptor occu ...
Voir le projet

 8

 TERMINÉ 

European Prevention of Alzheimer’s Dementia Consortium (EPAD)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,

Background:The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression defined by biomarker evidence of AD pathology and no or only minimal clinical symptoms and engage them in a standing adaptive clinical trial, of the highest quality, testing multiple interventions. To achieve this, EPAD will also provide the analytical infras ...
Voir le projet

 40

 TERMINÉ 

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases (PRECISESADS)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,

We concur to the IMI on “Reclassification of SLE, connective tissue diseases and RA” call by presenting a proposal aimed at using the power of OMICs, and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. Such knowledge has not been applied to individual patients, depriving them from potential benefits in terms of the use of new therape ...
Voir le projet

 30

 TERMINÉ 

Aetionomy – Organising Mechanistic Knowledge about Neurodegenerative Diseases for the Improvement of Drug Development and Therapy (AETIONOMY)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2018,

IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this call, we propose (I) the development of a generic AETIONOMY pipeline to capture and infer over mechanistic knowledge of pathophysiology, and (II) the focused application of this pipeline to derive clinically significant mechanistic taxonomies of neurodegenerativ ...
Voir le projet

 20

 TERMINÉ 

European Medical Information Framework (EMIF)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information gaps which prevent their full exploitation. EMIF aim ...
Voir le projet

 64

 TERMINÉ 

European Lead Factory (EUC²LID)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as starting points for subsequent optimization to either drug candidates or high-quality pharmacological tools for the experimental validation of targets. The concept intends to bridge academic and applied research interests. The European Lead Factory will provi ...
Voir le projet

 34

 TERMINÉ 

Recognising Adverse Drug Reactions (WEB-RADR)

Date du début: 1 sept. 2014, Date de fin: 31 août 2017,

WEB-RADR is a consortium of leading experts in pharmacovigilance from regulatory agencies, research, academia and patient support groups. Together with EFPIA partners our aims will be to set policy & guidance and deliver robust information technology tools to address the potential for the reporting of adverse drug reactions (ADRs) through mobile applications and the recognition of drug safety sign ...
Voir le projet

 20

 TERMINÉ 

Continuous Catalytic Transformations: from optimization in MICRO systems to INDustrial production (CCT-MicroIndus)

Date du début: 1 sept. 2013, Date de fin: 31 août 2017,

...f Bordeaux 1, France, where the Phoenics team of the Institut des Sciences Moléculaires is located. This development will be done in close collaboration with the enabling chemical technology team of UCB Pharma in Braine l’Alleud, Belgium.Once optimized, systems will be implemented to larger scale production chains. Two mains reactions will be studied in this project, the Friedel Craft /Mannich rea ...
Voir le projet

 3

 TERMINÉ 

BeTheCuRE (BTCURE)

Date du début: 1 avr. 2011, Date de fin: 31 mars 2017,

BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal models have to develop the line with the different subsets of the human diseases in order to be optimally used for drug discovery and drug evaluation. Our aim is to develop an understanding of the early process in human arthritis subsets and the animal models that ...
Voir le projet

 41

 TERMINÉ 

Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk (ABIRISK)

Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,

The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recru ...
Voir le projet

 39

 TERMINÉ 

Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP-DILI)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,

The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will address this situation by the development of innovative preclinical test systems which are both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans. An iterative, tiered approach with respect to test compounds, test sys ...
Voir le projet

 29

 TERMINÉ 

European Patients' Academy on Therapeutic Innovation (EUPATI)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,

"The proposed project ""European Patients' Academy on Therapeutic Innovation"" (EUPATI) contributes to IMI’s goal of raising patients’ awareness and participation in pharmaceutical R&D. This patient-led academy will provide scientifically reliable, objective, comprehensive information to patients on pharmaceutical R&D. It will increase the capacity of well-informed patients to be effective advocat ...
Voir le projet

 33

 TERMINÉ 

Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities (ETOX)

Date du début: 1 janv. 2010, Date de fin: 31 déc. 2016,

The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological profiles of new molecular entities in early stages of the drug development pipeline. This will be achieved by coordinating the efforts of specialists from academia and SMEs in the wide scope of disciplines that are required to move towards a more reliable modell ...
Voir le projet

 30

 TERMINÉ 

European Bank for induced pluripotent Stem Cells (EBISC)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2016,

EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, data and cell services. Its goal is to demonstrate an operational banking and distribution service of iPSC lines after 3 years and to establish subsequently for Europe a centralised, not-for-profit bank providing all qualified users with access to scalable, cos ...
Voir le projet

 30

 TERMINÉ 

European Modular Education and Training Programme in Safety Sciences for Medicines (SAFESCIMET)

Date du début: 1 janv. 2010, Date de fin: 30 nov. 2016,

Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Voir le projet

 34

 TERMINÉ 

European Medicines Research Training Network (EMTRAIN)

Date du début: 1 oct. 2009, Date de fin: 30 sept. 2016,

EMTRAIN is an essential element for the success of the IMI Education & Training (E&T) Call Topics in Europe (current and future). It will establish a pan-European platform of excellence for education and training covering the whole life-cycle of medicines from basic research through clinical development to pharmaco-vigilance. It will underpin the successful delivery of the current and future IMI-f ...
Voir le projet

 32

 TERMINÉ 

Drug Disease Model Resources (DDMORE)

Date du début: 1 mars 2011, Date de fin: 31 août 2016,

Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making.M&S facilitates the continuous integration of available information related to a drug or disease into constantly-evolving mathematical models capa ...
Voir le projet

 28

 TERMINÉ 

European programme in Pharmacovigilance and Pharmacoepidemiology (EU2P)

Date du début: 1 sept. 2009, Date de fin: 30 juin 2016,

The Eu2P training network in Pharmacovigilance and Pharmacoepidemiology will meet the needs of industry,regulatory authorities and academia at the European level. It will give access to a harmonised training programme that gathers complementary specialized and eminent European partners. The Eu2P consortium consists of course providers with aproven record including the University of Bordeaux (Eu2P ...
Voir le projet

 24

 TERMINÉ 

Physical Activity as a Crucial Patient Reported Outcome in COPD (PRO- ACTIVE)

Date du début: 1 sept. 2009, Date de fin: 31 mai 2016,

Physical activity (PA) is essential in maintaining optimal health in chronic diseases, including COPD.More physically active patients have less hospital admissions and better survival. Validated physicalactivity monitors have become available in recent years, and together with patient report of symptomsand distress of physical (in)activity, this may form a potent new Patient Reported Outcome (PRO) ...
Voir le projet

 20

 TERMINÉ 

Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development (PHARMA-COG)

Date du début: 1 janv. 2010, Date de fin: 31 déc. 2015,

PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision bef ...
Voir le projet

 38

 TERMINÉ 

Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED)

Date du début: 1 oct. 2009, Date de fin: 30 sept. 2015,

RationaleThe inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma this bottleneck results from: a lack of useful and validated biomarkers, underperforming pre-clinical models, inadequate and incomplete sub-phenotyping, and insufficient disease understanding.HypothesisThe use of biomarker profiles comprised of various types of hi ...
Voir le projet

 42

 TERMINÉ 

Understanding chronic pain and improving its treatment (EUROPAIN)

Date du début: 1 oct. 2009, Date de fin: 30 sept. 2015,

We will establish an international team of leading researchers and clinicians (EuroPain) to undertake multidisciplinary translational research which will: 1) increase the understanding of chronic pain mechanisms; 2)facilitate the development of novel analgesic drugs; and 3) improve the treatment of chronic pain patients.Nineteen researchers drawn from the London Pain Consortium, the Danish Pain Re ...
Voir le projet

 29

 TERMINÉ 

bioMARkers and molecular tumor classification for non-genotoxic CARcinogenesis (MARCAR)

Date du début: 1 janv. 2010, Date de fin: 30 juin 2015,

MARCAR aims to establish reliable early markers and molecular classification of tumors in non genotoxic carcinogenesis, applying a mechanism-based approach. Benefits are improved drug safety, more efficient drug development, and progress with 3 R issues. MARCAR focuses on rodent liver, the major target organ of non-genotoxic carcinogens (NGC). However, this approach will facilitate predictions for ...
Voir le projet

 12

 TERMINÉ 

Integrating research training in particle & powder technology to deliver efficient products with high functionality (POWTECH)

Date du début: 1 mars 2011, Date de fin: 28 févr. 2015,

"Approximately 80% of all products are or were a particle at some point in their processing lifetime. Particle and colloid technology has been described as the ""Growth Engine of Tomorrow"" with the market projected to grow from $2T to $10Tr over the next decade. Alongside with this challenge, the number of researchers active in powder technology is limited and only a few universities, public and ...
Voir le projet

 16

 TERMINÉ 

Pharmaceutical Medicine Training Programme (PHARMATRAIN)

Date du début: 1 mai 2009, Date de fin: 30 avr. 2014,

"The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug development for all professionals involved, incl. physicians, pharmaceutical scientists,biologists, biometricians, health economists, and safety and regulatory scientists from universities, regulatory agencies, large, middle-sized and small pharmaceutical enterprises, ...
Voir le projet

 52

 TERMINÉ 

Foldamers against protein-protein interactions (FOLDAPPI)

Date du début: 1 févr. 2009, Date de fin: 31 janv. 2014,

...tance as a drug target, no small molecule inhibitor of the Il-4/IL-4R has been reported so far, warranting the use of foldamers to do the same. The three partners involved in this cooperation, namely UCB Pharma, Université Bordeaux I and Universität Würzburg each have unique expertises necessary to bring this project to completion. This combination will produce breakthrough knowledge and insights ...
Voir le projet

 5

 TERMINÉ 

New Molecular Purification Technology for Pharmaceutical Production (NEMOPUR)

Date du début: 1 sept. 2008, Date de fin: 31 août 2012,

"The NEMOPUR Initial Training Network will focus on creating a new generation of molecular purification technologies for Active Pharmaceutical Ingredient (API) manufacture, with a particular focus on removal of organic impurities from API production. New membranes with improved chemical stability in a wide range of solvents, and better controlled cutoff properties, novel molecularly imprinted poly ...
Voir le projet

 9

 TERMINÉ 

Monoclonal ANTIbody-targeted CARBon nanobues against cancer (ANTICARB)

Date du début: 1 mars 2008, Date de fin: 31 août 2011,

"ANTICARB attempts to exploit the advantages offered by a novel nanotechnology platform – carbon nanotubes – and apply them to a clinically established therapeutic modality – targeted antibody therapy – for the creation of hybrid nanotechnology-based monoclonal antibody targeted cancer therapeutics. ANTICARB combines two emerging technologies, antibody and nanotube technology, in a way that will a ...
Voir le projet

 8